Larimar Therapeutics (LRMR) Accumulated Expenses (2013 - 2025)

Larimar Therapeutics' Accumulated Expenses history runs 13 years deep, the most recent figure standing at $58.5 million for Q4 2025.

• Quarterly Accumulated Expenses rose 1696.99% year-over-year to $58.5 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $58.5 million (up 1696.99% YoY) and the FY2025 annual result came in at $58.5 million, up 1696.99% from the prior year.
• Accumulated Expenses was $58.5 million for Q4 2025 at Larimar Therapeutics, up from $32.9 million in the prior quarter.
• Across five years, Accumulated Expenses topped out at $58.5 million in Q4 2025 and bottomed at $788000.0 in Q1 2024.
• A 5-year average of $9.4 million and a median of $4.5 million in 2021 frame the typical range for Accumulated Expenses.
• Annual changes were most pronounced in 2024 — Accumulated Expenses sank 88.28% — and 2025, when it soared 2281.22%.
• Larimar Therapeutics' Accumulated Expenses stood at $1.1 million in 2021, then surged by 86.34% to $2.0 million in 2022, then rose by 15.59% to $2.4 million in 2023, then soared by 37.59% to $3.3 million in 2024, then jumped by 1696.99% to $58.5 million in 2025.
• Business Quant data shows LRMR's Accumulated Expenses at $58.5 million in Q4 2025, $32.9 million in Q3 2025, and $21.4 million in Q2 2025.